CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...
Phase 2
London, United Kingdom and 25 other locations
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
London, United Kingdom and 145 other locations
Patients with relapsed/refractory multiple myeloma will be enrolled in a dose-escalation phase receiving monotherapy CID-103. Once ...
Phase 1
London, United Kingdom and 3 other locations
profile of daratumumab when given in combination with Lenalidomide and dexamethasone in participants with relapsed or relapsed and refractory Multiple...
Phase 1, Phase 2
London, United Kingdom and 7 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
London, United Kingdom and 59 other locations
progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...
Phase 3
London, United Kingdom and 211 other locations
doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment o ...
Phase 2
London, United Kingdom and 41 other locations
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...
Phase 1
London, Greater London, United Kingdom and 30 other locations
phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...
Phase 1
London, United Kingdom and 40 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
Reading, United Kingdom and 238 other locations
Clinical trials
Research sites
Resources
Legal